DOCKET NO.: 48378-0003-00-&S PATENT

Application No.: 10/621,711

Supplemental amendment after RCE

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-162. (Canceled)

163. (Currently amended) A transdermal delivery system comprising a backing

layer and an adhesive polymer matrix containing progestin and estrogen hormones to be

transdermally delivered affixed to the backing layer, wherein the adhesive polymer matrix

comprises an adhesive polymer, a humectant, the progestin, the estrogen, and up to about

30% by weight of a combination of skin permeation enhancing agents comprising dimethyl

sulfoxide, a fatty (C₈-C₂₀) alcohol ester of lactic acid, a lower (C₁-C₄) alkyl ester of lactic

acid, and capric acid.

(a) an adhesive polymer;

(b) a humectant;

(c)a combination of skin permeation enhancing agents comprising dimethyl

sulfoxide; a fatty (C₈-C₂₀) alcohol ester of lactic acid; a lower (C₁-C₄) alkyl-ester of

lactic acid; and capric acid;

(d) a progestin; and

(e) an estrogen.

164. (Previously presented) The transdermal delivery system of claim 163,

wherein the adhesive polymer is a polyacrylate copolymer, a polyisobutylene or a silicone

adhesive.

165. (Previously presented) The transdermal delivery system of claim 164,

wherein the polyacrylate copolymer comprises a 2-ethylhexyl acrylate monomer.

166. (Previously presented) The transdermal delivery system of claim 165,

wherein the polyacrylate copolymer further comprises about 3 to 60% w/w vinyl acetate.

167. (Previously presented) The transdermal delivery system of claim 163,

wherein the humectant comprises polyvinylpyrrolidone.

Page 3 of 10

DOCKET NO.: 48378-0003-00-&S

Application No.: 10/621,711

Supplemental amendment after RCE

168. (Previously presented) The transdermal delivery system of claim 167, wherein the humectant comprises a polyvinylpyrrolidone copolymer.

PATENT

- 169. (Previously presented) The transdermal delivery system of claim 168, wherein the humectant is a polyvinylpyrrolidone/vinyl acetate copolymer.
- 170. (Previously presented) The transdermal delivery system of claim 169, wherein the polyvinylpyrrolidone is formulated in an amount of about 60% w/w and the vinyl acetate is formulated in an amount of about 40% w/w in the polyvinylpyrrolidone/vinyl acetate copolymer.
- 171. (Previously presented) The transdermal delivery system of claim 163, wherein the fatty alcohol ester of lactic acid is lauryl lactate.
- 172. (Previously presented) The transdermal delivery system of claim 163, wherein the lower alkyl ester of lactic acid is ethyl lactate.
- 173. (Previously presented) The transdermal delivery system of claim 163, wherein the progestin is levonorgestrel.
- 174. (Previously presented) The transdermal delivery system of claim 163, wherein the estrogen is ethinyl estradiol or 17 β -estradiol.
- 175. (Previously presented) The transdermal delivery system of claim 173, which, when applied to the skin of a human, once each week, consecutively over a period of three or more weeks, deliver *in vivo* an average serum concentration of over 1000 pg/ml of levonorgestrel.
- 176. (New) The transdermal delivery system of claim 163, wherein the adhesive polymer matrix comprises more than 10% and less than about 30% by weight of the combination of skin permeation enhancing agents.

DOCKET NO.: 48378-0003-00-&S

Application No.: 10/621,711

Supplemental amendment after RCE

177. (New) The transdermal delivery system of claim 163, wherein the adhesive polymer matrix comprises about 18% to about 30% by weight of the combination of skin permeation enhancing agents.

PATENT

- 178. (New) The transdermal delivery system of claim 163, wherein the adhesive polymer matrix comprises about 21% to about 27% by weight of the combination of skin permeation enhancing agents.
- 179. (New) The transdermal delivery system of claim 163, wherein the adhesive polymer matrix is formulated by combining the adhesive polymer, the humectant, the progestin, the estrogen, and about 10% to about 30% by weight of the combination of skin permeation enhancing agents.
- 180. (New) The transdermal delivery system of claim 163, wherein the adhesive polymer matrix is formulated by combining the adhesive polymer, the humectant, the progestin, the estrogen, and about 13% to about 27% by weight of the combination of skin permeation enhancing agents.